Navigation Links
ARIUS recognized for entrepreneurial excellence
Date:4/7/2008

Dr. David S. Young awarded "Most Innovative" award by the Association of

Chinese Canadian Entrepreneurs

TORONTO, April 7 /PRNewswire-FirstCall/ - ARIUS Research Inc. (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that Dr. David S. Young, President and Chief Executive Officer, received the "Most Innovative" award at the Chinese Canadian Entrepreneur Awards, held on April 5th, 2008 in Toronto, Ontario.

"The FunctionFIRST(TM) antibody discovery platform pioneered by our CEO is the foundation of our company and exemplifies the exceptional innovation that this award honours," said Warren Whitehead, Chief Financial Officer of ARIUS. "As we transition to a clinical company this year, we are proud that ARIUS' mission to generate and develop anti-cancer, antibody drugs has been recognized through this honour."

The Chinese Canadian Entrepreneur Awards, sponsored by the Association of Chinese Canadian Entrepreneurs (ACCE), annually recognizes high achievements by business people and entrepreneurs who have strengthened the competitiveness of Chinese Canadian business community in the global market. The Most Innovative Award is presented to an individual, team of individuals or company who have demonstrated exceptional innovation in their given field and contributed great value to the marketplace.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com.

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at http://www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.


'/>"/>
SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
2. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
3. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
4. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
5. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
6. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
7. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
8. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
9. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
10. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
11. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology:
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
Breaking Biology News(10 mins):